Metabolite Profiling of LADA Challenges the View of a Metabolically Distinct Subtype

Author:

Al-Majdoub Mahmoud1,Ali Arslan12,Storm Petter3,Rosengren Anders H.4,Groop Leif15,Spégel Peter16

Affiliation:

1. Unit of Molecular Metabolism, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden

2. H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan

3. Diabetes and Endocrinology, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden

4. Translational Diabetes Research, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden

5. Finnish Institute for Molecular Medicine (FIMM), Helsinki University, Helsinki, Finland

6. Centre for Analysis and Synthesis, Department of Chemistry, Lund University, Lund, Sweden

Abstract

Latent autoimmune diabetes in adults (LADA) usually refers to GAD65 autoantibodies (GADAb)–positive diabetes with onset after 35 years of age and no insulin treatment within the first 6 months after diagnosis. However, it is not always easy to distinguish LADA from type 1 or type 2 diabetes. In this study, we examined whether metabolite profiling could help to distinguish LADA (n = 50) from type 1 diabetes (n = 50) and type 2 diabetes (n = 50). Of 123 identified metabolites, 99 differed between the diabetes types. However, no unique metabolite profile could be identified for any of the types. Instead, the metabolome varied along a C-peptide–driven continuum from type 1 diabetes via LADA to type 2 diabetes. LADA was more similar to type 2 diabetes than to type 1 diabetes. In a principal component analysis, LADA patients overlapping with type 1 diabetes progressed faster to insulin therapy than those overlapping with type 2 diabetes. In conclusion, we could not find any unique metabolite profile distinguishing LADA from type 1 and type 2 diabetes. Rather, LADA was metabolically an intermediate of type 1 and type 2 diabetes, with those patients closer to the former showing a faster progression to insulin therapy than those closer to the latter.

Funder

Royal Physiographic Society of Lund

Novo Nordisk Foundation

Påhlsson Foundation

The Swedish Diabetes Foundation

Crafoord Foundation

Erasmus Mundus Europe-Asia

Swedish Research Council

Linnéus grant

strategic research grant

ERC Advanced Researcher grant

Knut and Alice Wallenberg Foundation

Publisher

American Diabetes Association

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3